AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
193.83
-0.02 (-0.01%)
At close: 4:00PM EST

193.57 -0.26 (-0.13%)
Pre-Market: 8:06AM EST

Stock chart is not supported by your current browser
Previous Close193.85
Open193.85
Bid193.35 x 800
Ask210.00 x 1000
Day's Range193.38 - 194.43
52 Week Range114.27 - 194.61
Volume2,167,721
Avg. Volume2,284,812
Market Cap63.63B
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-27.98
Earnings DateJan 26, 2020 - Jan 30, 2020
Forward Dividend & Yield2.96 (1.54%)
Ex-Dividend DateNov 10, 2019
1y Target Est189.71
  • PR Newswire

    SkinMedica® Launches New Instant Bright Eye Cream For Immediate, Visible Results

    Allergan plc (NYSE: AGN) announced today the launch of the SkinMedica® Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens and helps visibly firm the appearance of the delicate skin around the eyes. The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time—including dark circles, fine lines and crepiness of upper eyelids. For its most comprehensive regimen, SkinMedica® is also introducing Instant Bright Eye Mask, a set of hydrogel eye patches that reduce the appearance of puffiness and provide a hydrating boost for under the eyes.

  • Is Allergan (AGN) a Great Stock for Value Investors?
    Zacks

    Is Allergan (AGN) a Great Stock for Value Investors?

    Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

  • J&J Seeks Label Expansion for Spravato Nasal Spray in EU
    Zacks

    J&J Seeks Label Expansion for Spravato Nasal Spray in EU

    J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

  • Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living
    PR Newswire

    Allergan Teams Up With Super Bowl MVP Von Miller to Raise Awareness of Glaucoma's Impact on Daily Living

    Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the 'My Glaucoma' campaign, Miller will address the misunderstandings and impact of glaucoma and encourage those with the disease, and their caregivers, to take early action. This includes going regularly to the doctor and taking medications as prescribed. Additional information can be found at www.MyGlaucoma.com.

  • 3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio
    Zacks

    3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio

    Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...

  • Moody's

    AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of AbbVie Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of AbbVie Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
    Zacks

    Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

    Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

  • Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
    Zacks

    Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

    Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

  • Benzinga

    The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 8.) Allergan plc (NYSE: AGN ):  AbbVie Inc ...

  • MarketWatch

    AbbVie to separate Botox in new aesthetics unit; Brent Saunders won't have role

    Shares of AbbVie Inc. and Allergan plc were both up about 1% in trading on Wednesday after AbbVie announced new plans for the combined company once the pending $63 billion acquisition of Allergan closes. It's the first time the company has shared leadership plans since confirming that Richard Gonzalez would stay in his role as CEO of AbbVie. Allergan CEO Brent Saunders will be on the board of directors but does not have a role in the combined company, according to an AbbVie spokeswoman. One Allergan executive, Carrie Strom, will join the executive leadership team of the combined company; the other eight members are AbbVie executives. Strom will lead the newly created Allergan Aesthetics, a separate Irvine, Calif.-based business for Botox and the other Allergan medical aesthetics treatments. It will also conduct its own research and development. Allergan's other therapies, including Botox for indications other than aesthetics, the antipsychotic Vraylar and irritable bowel syndrome drug Linzess, will be folded into AbbVie, which is based in North Chicago. The deal is expected to close this quarter. Over the last year, Allergan's stock is up 31%, and AbbVie's stock is down 1%. The S&P 500 has gained 27% over the last 52 weeks.

  • Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101
    Zacks

    Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101

    Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.

  • Amgen Stock Up in a Year on Pipeline & Biosimilar Progress
    Zacks

    Amgen Stock Up in a Year on Pipeline & Biosimilar Progress

    Pipeline development and rapid progress in biosimilars program drive Amgen's (AMGN) stock 24% higher in the past year.

  • Business Wire

    Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Allergan plc (NYSE: AGN) announced today that the companies have reached an agreement with Sandoz Inc. (Sandoz) resolving patent litigation brought in response to Sandoz’s abbreviated new drug application (ANDA) seeking approval to market generic versions of LINZESS (linaclotide) prior to the expiration of the companies’ applicable patents. The settlement with Sandoz is the fourth patent infringement settlement the companies have reached with respect to LINZESS.